Immediate Impact
64 standout
Citing Papers
Role of SLC7A11/xCT in Ovarian Cancer
2024 Standout
Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment
2024 Standout
Works of Tina Rizack being referenced
A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study
2017
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study
2017
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| Tina Rizack | 123 | 51 | 37 | 63 | 53 | 19 | 319 | |
| R.V. Iaffaioli | 131 | 81 | 33 | 21 | 44 | 26 | 312 | |
| Lisa M. Moy | 154 | 30 | 53 | 24 | 25 | 18 | 310 | |
| M. Katayoon Rezaei | 55 | 127 | 16 | 12 | 34 | 22 | 280 | |
| J. G. Williamson | 25 | 45 | 16 | 18 | 29 | 15 | 322 | |
| Xiaoming Cao | 119 | 61 | 70 | 7 | 26 | 27 | 335 | |
| P Helman | 133 | 63 | 45 | 10 | 14 | 24 | 358 | |
| A. Jones | 129 | 23 | 63 | 12 | 12 | 14 | 329 | |
| Wen‐Shiung Liou | 55 | 62 | 23 | 8 | 31 | 25 | 289 | |
| Bogdan Michalski | 130 | 37 | 35 | 9 | 28 | 18 | 302 | |
| Sayeh Lavasani | 158 | 49 | 87 | 8 | 23 | 23 | 291 |
All Works
Loading papers...